AC   CVCL_4380
SY   SUDHL7; SUDHL-7; SuDHL 7; Stanford University-Diffuse Histiocytic Lymphoma-7; DHL-7; DHL7
DR   cancercelllines; CVCL_4380
DR   Cosmic; 850206
DR   Cosmic; 1290018
DR   Cosmic; 1517608
DR   Cosmic; 1541912
DR   Cosmic; 1945193
DR   Cosmic; 2276341
DR   Cosmic; 2361373
DR   DSMZ; ACC-903
DR   DSMZCellDive; ACC-903
DR   GEO; GSM380148
DR   GEO; GSM552466
DR   GEO; GSM1035335
DR   Progenetix; CVCL_4380
DR   Wikidata; Q54970722
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=83902;
RX   PubMed=214220;
RX   PubMed=371794;
RX   PubMed=3881165;
RX   PubMed=8547074;
RX   PubMed=9787181;
RX   PubMed=19278952;
RX   PubMed=19358282;
RX   PubMed=20628145;
RX   PubMed=23292937;
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00557.
CC   Doubling time: ~50 hours (DSMZ=ACC-903).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: Was reported in the Cellosaurus and the ICLAC Register (from 2018 to early 2022) to be a SU-DHL-8 contaminated cell line but there seem to have been an issue with the sample tested. DSMZ has obtained original stock from Epstein A.L. and SU-DHL-7 is a genuine non-problematic cell line.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12,13
ST   D16S539: 9,12
ST   D18S51: 14,15
ST   D19S433: 12,14
ST   D21S11: 32.2
ST   D2S1338: 16,20
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D7S820: 10,11
ST   D8S1179: 12,14
ST   FGA: 20,25
ST   Penta D: 13
ST   Penta E: 12,15
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
RX   PubMed=83902; DOI=10.1002/1097-0142(197901)43:1<1::AID-CNCR2820430102>3.0.CO;2-M;
RA   Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.;
RT   "Biology and virology of the human malignant lymphomas: 1st Milford D.
RT   Schulz Lecture.";
RL   Cancer 43:1-24(1979).
RX   PubMed=214220; DOI=10.1002/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4;
RA   Epstein A.L., Levy R., Kim H., Henle W., Henle G., Kaplan H.S.;
RT   "Biology of the human malignant lymphomas. IV. Functional
RT   characterization of ten diffuse histiocytic lymphoma cell lines.";
RL   Cancer 42:2379-2391(1978).
RX   PubMed=371794;
RA   Epstein A.L., Kaplan H.S.;
RT   "Feeder layer and nutritional requirements for the establishment and
RT   cloning of human malignant lymphoma cell lines.";
RL   Cancer Res. 39:1748-1759(1979).
RX   PubMed=3881165; DOI=10.1016/0165-4608(85)90186-4;
RA   Kaiser-McCaw Hecht B., Epstein A.L., Berger C.S., Kaplan H.S.,
RA   Hecht F.;
RT   "Histiocytic lymphoma cell lines: immunologic and cytogenetic
RT   studies.";
RL   Cancer Genet. Cytogenet. 14:205-218(1985).
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
RX   PubMed=23292937; DOI=10.1073/pnas.1205299110;
RA   Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L.,
RA   Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G.,
RA   Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P.,
RA   Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I.,
RA   Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J.,
RA   Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S.,
RA   Dunson D.B., Dave S.S.;
RT   "Genetic heterogeneity of diffuse large B-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).